All In Biotech

Drug Trial Radar · NCT05093933

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)

A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 6,106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,106

Actual

Start

Nov 2, 2021

Primary completion

Nov 20, 2024

Study completion Feb 5, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.

Conditions

  • Chronic Heart Failure With Reduced Ejection Fraction

Interventions

  • VericiguatDrug

    2.5, 5.0, or 10.0 mg orally once daily

  • PlaceboDrug

    0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization: Participants With an Event Per 100 Patient-YearsTime frame: Up to approximately 36 months (from randomization to the primary completion data cutoff)

Locations

519 sites in 36 countries. Site status is shown where the registry gives one.

  • Advanced Cardiovascular - Alexander City ( Site 0038)

    Alexander City, Alabama

  • University of Alabama at Birmingham - School of Medicine-Cardiology ( Site 0153)

    Birmingham, Alabama

  • Heart Center Research, LLC ( Site 0156)

    Huntsville, Alabama

  • Mercy Gilbert Medical Center-Dignity Health Cardiology ( Site 0075)

    Gilbert, Arizona

  • Valley Clinical Trials, Inc. ( Site 0085)

    Covina, California

  • VA West Los Angeles Medical Center-Cardiology ( Site 0149)

    Los Angeles, California

  • Valley Clinical Trials Inc ( Site 0006)

    Northridge, California

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center ( Site 0010)

    Torrance, California

  • Blue Coast Research Center ( Site 0053)

    Vista, California

  • Excel Medical Clinical Trials ( Site 0008)

    Boca Raton, Florida

  • Universal Axon Clinical Research, LLC ( Site 0022)

    Doral, Florida

  • Holy Cross Hospital ( Site 0100)

    Fort Lauderdale, Florida

  • Indago Research and Health Center Inc ( Site 0011)

    Hialeah, Florida

  • South Florida Research Solutions ( Site 0058)

    Hollywood, Florida

  • University of Florida - Jacksonville ( Site 0169)

    Jacksonville, Florida

  • East Coast Institute for Research, LLC ( Site 0047)

    Jacksonville, Florida

  • Cardiovascular Research Center of South Florida ( Site 0074)

    Miami, Florida

  • ProLive Medical Research ( Site 0032)

    Miami, Florida

  • Peace River Cardiovascular Center ( Site 0088)

    Port Charlotte, Florida

  • BAYCARE MEDICAL GROUP ( Site 0099)

    Safety Harbor, Florida

  • East Coast Institute for Research - St. Augustine ( Site 0016)

    Saint Augustine, Florida

  • Cardiovascular Center of Sarasota ( Site 0154)

    Sarasota, Florida

  • Emory University School of Medicine ( Site 0123)

    Atlanta, Georgia

  • IACT Health ( Site 0106)

    Columbus, Georgia

  • NSC Research ( Site 0068)

    Johns Creek, Georgia

  • Georgia Arrhythmia Consultants and Research Institute ( Site 0042)

    Macon, Georgia

  • Cardiovascular Consultants of South Georgia, LLC ( Site 0137)

    Thomasville, Georgia

  • Mount Sinai Hospital ( Site 0050)

    Chicago, Illinois

  • Chicago Medical Research ( Site 0086)

    Hazel Crest, Illinois

  • OSF Healthcare Cardiovascular Institute ( Site 0122)

    Peoria, Illinois

  • Methodist Medical Center of Illinois ( Site 0098)

    Peoria, Illinois

  • Franciscan Physician Network - Indiana Heart Physicians ( Site 0087)

    Indianapolis, Indiana

  • The Heart Center of Lake County Research Institute-Research ( Site 0147)

    Merrillville, Indiana

  • Cardiovascular Research of Northwest Indiana ( Site 0036)

    Munster, Indiana

  • Reid Physician Associates ( Site 0054)

    Richmond, Indiana

  • University of Iowa ( Site 0005)

    Iowa City, Iowa

  • Alliance for Multispecialty Research, LLC ( Site 0143)

    Wichita, Kansas

  • Norton Healthcare-Norton Heart Specialist ( Site 0062)

    Louisville, Kentucky

  • Cambridge Medical Trials ( Site 0041)

    Alexandria, Louisiana

  • Louisiana Heart Center - Hammond ( Site 0004)

    Hammond, Louisiana

Showing 40 of 519 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.